Can multiple sclerosis be diagnosed on a first demyelinating event?

被引:0
|
作者
de Seze, J [1 ]
机构
[1] Hop Roger Salengro, Neurol Clin, F-59037 Lille, France
来源
PRESSE MEDICALE | 2004年 / 33卷 / 03期
关键词
D O I
10.1016/S0755-4982(04)98518-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progression is required The definition of multiple sclerosis (MS) relies on the notion of temporo-spatial dissemination of inflammatory demyelinating neurological episodes. Until recently, in order to retain the diagnosis of definite MS, two successive neurological episodes had to be observed in two different territories. Since the commercialisation of new immunomodulating treatments, and in particular the recent demonstration of their efficacy in delaying the onset of a second neurological episode, it has been necessary to draw-up new criteria. New criteria have recently been proposed by a group of experts and they emphasize the fundamental role played by magnetic resonance imaging. New priorities With these new criteria, certain aspects have become front-line. This is the case of the necessity of foreseeing more exhaustive differential diagnoses of MS, so as to avoid the erroneous initiation of a specific treatment. There is also the problem of the selection of patients at high risk of a potentially progressive MS, not all patients necessarily require such treatment at the start. Updating We successively present the recently revised diagnostic criteria in order to be able to diagnose MS after the first demyelinising episode, we then study the clinical and paraclinical predictive elements that provide supplementary support for MS and, notably, progressive MS. We also discuss the differential diagnoses to be excluded according to the clinical context and, lastly, we will attempt to assess the practical consequences of an early diagnosis, not only with regard to its announcement, but also with regard to the therapeutic decisions to be made. (C) 2004, Masson, Paris.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 50 条
  • [1] Multimodal evoked potentials as a multiple sclerosis biomarker after a first demyelinating event
    Mrabet, Saloua
    Mednini, Mariem
    Souissi, Amira
    Atrous, Amal
    Gharbi, Alya
    Nasri, Amina
    Berrechid, Amina Gargouri
    Kacem, Imen
    Gouider, Riadh
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [2] Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis
    Chapman, Caron
    Lucas, Robyn M.
    Ponsonby, Anne-Louise
    Taylor, Bruce
    [J]. BRAIN COMMUNICATIONS, 2022, 4 (04)
  • [3] JC virus and multiple sclerosis:: a study in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event
    Olmos, Y
    Alvarez-Lafuente, R
    García-Montojo, M
    de las Heras, V
    Bartolomé, M
    Arroyo, R
    [J]. MULTIPLE SCLEROSIS, 2005, 11 : S133 - S134
  • [4] JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event
    Alvarez-Lafuente, Roberto
    Garcia-Montojo, Marta
    De Las Heras, Virginia
    Bartolome, Manuel
    Arroyo, Rafael
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (05) : 590 - 595
  • [5] Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
    Berger, T
    Rubner, P
    Schautzer, F
    Egg, R
    Ulmer, H
    Mayringer, I
    Dilitz, E
    Deisenhammer, F
    Reindl, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02): : 139 - 145
  • [6] Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis
    Villacieros-Alvarez, Javier
    Espejo, Carmen
    Arrambide, Georgina
    Castillo, Mireia
    Carbonell-Mirabent, Pere
    Rodriguez, Marta
    Bollo, Luca
    Castillo, Joaquin
    Comabella, Manuel
    Galan, Ingrid
    Midaglia, Luciana
    Mongay-Ochoa, Neus
    Nos, Carlos
    Rio, Jordi
    Rodriguez-Acevedo, Breogan
    Sastre-Garriga, Jaume
    Tur, Carmen
    Vidal-Jordana, Angela
    Vilaseca, Andreu
    Zabalza, Ana
    Auger, Cristina
    Rovira, Alex
    Montalban, Xavier
    Tintore, Mar
    Cobo-Calvo, Alvaro
    [J]. ANNALS OF NEUROLOGY, 2024, 95 (01) : 116 - 128
  • [7] Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
    Clerico, M.
    Faggiano, F.
    Palace, J.
    Rice, G.
    Tintore, M.
    Durelli, L.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02):
  • [8] Longitudinal assessment of autonomic nervous system in patients with first demyelinating event suggestive of multiple sclerosis
    Habek, M.
    Crnosija, L.
    Gabelic, T.
    Barun, B.
    Adamec, I
    Junakovic, A.
    Ruska, B.
    Pavicic, T.
    Skoric, M. Krbot
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (11) : 1377 - 1383
  • [9] Validation of McDonald 2017 multiple sclerosis diagnostic criteria in patients with a first demyelinating event in Argentina
    Marrodan, M.
    Piedrabuena, M. A.
    Carnero Contentti, E.
    Fiol, M. P.
    Ysrraelit, M. C.
    Peuchot, V.
    Correale, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 695 - 696
  • [10] Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event
    Recai Türkoğlu
    Gülçin Benbir
    Selen Özyurt
    Erdil Arsoy
    Ece Akbayır
    Selin Turan
    Derya Karadeniz
    Vuslat Yılmaz
    Mehmet Gencer
    Erdem Tüzün
    [J]. International Ophthalmology, 2020, 40 : 151 - 158